Boost to Melanoma Services in the Riverina
12 December 2019
Melanoma patients and their families throughout the Riverina region will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia..
The merger was announced at the 10th Anniversary Celebrations for the Amie St Clair Melanoma Trust, which was formed by Annette and Peter St Clair in memory of their daughter Amie who passed away from melanoma when she was just 23 years old.
It will provide immediate benefits by doubling the level of services provided to melanoma patients in the Riverina, including:
- Increased capacity of the free melanoma nursing services;
- The establishment of clinical trials in Wagga Wagga;
- Opportunities for melanoma patients within the region to contribute to MIA research;
- Melanoma Education opportunities – both professional (GPs/Clinics) and community-based through the SunSafe Student Ambassador program.
The merged entity will retain its local office presence in Wagga Wagga, as well as the dedicated service of both Annette and Peter St Clair. Importantly, the legacy of Amie St Clair will be maintained.
Annette St Clair said she is excited by the opportunities created through MIA. ‘Pete and I just can’t believe we will have clinical trials established here and we are really excited that MIA is using the Amie St Clair Trust model as the framework to increase services in other parts of regional Australia,'
‘Our wonderful volunteers have worked so hard to build the Amie St Clair Melanoma Trust over the last 10 years, and this partnership with MIA will significantly increase melanoma services for the next 10 years.’
Melanoma Institute Australia CEO Matthew Browne attended the 10th Anniversary Celebrations and paid tribute to the tireless work of Annette and Peter St Clair, plus the all the volunteers, in raising awareness of melanoma and supporting local patients and their families.
‘We love what the Amie St Clair Melanoma Trust has been doing and together we have built a strong relationship over the past few years,’ Mr Browne said. ‘Our shared vision is zero deaths from melanoma, no matter where you live, and this is a fantastic opportunity to enhance the effective delivery of treatment and support services to melanoma patients in this region.
‘We can then go to Government with a proven collaborative model and hopefully extend melanoma support services to other regional centres as well.’
The newly merged entity will be officially launched at an event in Wagga on 27 February 2020 and its first major fundraising event will be Melanoma March Wagga on 15 March at Apex Park.
Pictured in photo: Annette St Clair and Moo, from Amie St Clair Melanoma Trust
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.